Drug Profile
Glycopyrrolate inhalation - NIOX
Alternative Names: Glycopyrronium bromide - NIOX; PSX 1002-GB; PSX-1002; PSX1002-GB pMDILatest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Prosonix
- Developer NIOX
- Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 23 Dec 2019 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 22 Jun 2015 Phase-II development is ongoing in United Kingdom
- 23 Jan 2014 Top-line efficacy & adverse events data from a phase II trial in Chronic obstructive pulmonary disease released by Prosonix